The Effect of Rosiglitazone on Ischemia-reperfusion-injury Using Annexin A5 Scintigraphy.
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Cardiovascular disease is the leading cause of death in diabetic patients due to both a high
event rate and a worse outcome. A pharmacological intervention that reduces
ischemia-reperfusion-injury would improve the outcome of diabetic patients after a
cardiovascular event. In the present study, we will use annexinA5 scintigraphy to address the
following hypothesis:
Rosiglitazone reduces ischemia-reperfusion-injury in humans with insulin resistance.